Edaravone in acute ischemic stroke, An Indian experience
- Author:
MK Sinha
;
Anuradha HK
;
R Juyal
;
R Shukla
;
RK Garg
;
AM Kar
- Publication Type:Journal Article
- From:Neurology Asia
2009;14(1):7-10
- CountryMalaysia
- Language:English
-
Abstract:
Background and Objective: This study aims to evaluate the safety and efficacy of edaravone, a novel
free radical scavenger, in a group of Indian patients of acute ischemic stroke. Methods: Twenty two
patients of acute ischemic stroke were given 30 mg of Edaravone twice daily for 14 days by infusion.
The outcome assessment was by the Modified Rankin Scale (MRS) and Barthel Index (BI). MRS
score ≤ 2 at 90 days was considered as a favorable outcome. Results: Fifteen patients (68%) had
favorable outcome. The mean MRS score decreased from 4.01±0.92 at baseline to 1.86±1.07 at day
90 (p<0.005). The mean Barthel index increased from 40.00±30.11 at baseline to 75.62±22.86 at
day 90 (p<0.005). The changes in the MRS and BI were observed from 7 days. None of the patients
experienced any adverse effect.
Conclusion: Edaravone treatment was safe and effective in providing early and sustained neurological
improvement in patients with acute ischemic stroke.
- Full text:P020150901527963321091.pdf
